37 results on '"Kojima, Kensuke"'
Search Results
2. Supplemental File 1 from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
3. Supplemental File 2 from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
4. Supplemental File 1 from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
5. Supplemental File 3 from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
6. Supplemental Information from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
7. Supplemental Information from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
8. Supplemental Figures 1 and 2 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
9. Data from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
10. Supplemental Methods from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
11. Supplemental File 2 from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
12. Supplementary Figure 1 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
13. Supplementary Figure 1 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
14. Supplemental Tables 1-8 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
15. Supplementary Figure 2 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
16. Supplemental Methods from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
17. Supplementary Tables 1-3 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
18. Supplementary Figure 3 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
19. Supplementary Tables 1-3 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
20. Supplemental Tables 1-8 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
21. Supplementary Figure 2 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
22. Supplementary Figure Legends from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
23. Data from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
24. Supplementary Figure 3 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
25. Data from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
26. Supplementary Figure Legends from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
27. Supplemental Figures 1 and 2 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
28. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
29. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
30. Abstract A130: Targeting BMI-1 by the novel BMI-1 inhibitor PTC596 in acute leukemia
31. Abstract B1: Gene expression and TP53 mutation analysis predict sensitivity of leukemia cells to MDM2 inhibition by DS-3032b
32. Abstract 340: Mitochondrial priming of new targeted agents in acute myeloid leukemia
33. Abstract A38: Steatohepatitis-associated hepatocellular carcinoma: Evidence of a keratin-based disease.
34. Abstract 3871: Insulin-like growth factor 1 receptor (IGF1R) inhibitor BMS754807 is active against FLT3-ITD mutated acute myelogenous leukemia and activity is p53 dependent
35. Abstract 3021: FLT3/ITD acute myeloid leukemia (AML) cells show C-MYC- and PIM-1-mediated CDC25A overexpression despite the presence of intrinsic DNA damage
36. The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
37. Mitogen-Activated Protein Kinase Kinase Inhibition Enhances Nuclear Proapoptotic Function of p53 in Acute Myelogenous Leukemia Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.